Get the latest news, insights, and market updates on CAPR (Capricor Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Capricor Therapeutics, Inc. (CAPR): A Bear Case Theory
We came across a bearish thesis on Capricor Therapeutics, Inc. on Alpha Talon Investment Research’s Substack by AT Investment Research. In this article, we will summarize the bulls’ thesis on CAPR. Capricor Therapeutics, Inc.’s share was trading at $26.55 as of December 15th. Capricor Therapeutics, Inc., a clinical-stage biotechnology company, develops transformative cell and exosome-based therapeutics for treating […] Dec 18, 2025 - $CAPR
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy
– Webinar to be held Wednesday, December 17, 2025, at 1:00 p.m. ET – SAN DIEGO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced that Parent Project Muscular Dystrophy (PPMD) will host a community webinar to share and discuss positive topline results from Capricor’s Phase 3 HOPE-3 trial evaluating Deramiocel, the Company’s investigational cell therapy for the treatm Dec 16, 2025 - $CAPR
How Recent Developments Are Rewriting the Story for Capricor Therapeutics
Capricor Therapeutics has seen its modeled fair value estimate jump from about $20.60 to roughly $44.56 per share, as analysts grow more confident in Deramiocel's path from the clinic to commercialization. Underpinning this upgrade are accelerated revenue growth assumptions, now closer to 156.4% versus 115.7% previously, along with a slightly higher discount rate near 7.03% that captures both the remaining risks and the richer opportunity set tied to HOPE-3 and potential priority review... Dec 6, 2025 - $CAPR
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the pricing of its underwritten public offering of 6,000,000 shares of common stock at a public offering price of $25.00 per share. Capricor also granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock at the public offering price, less the underwriting di Dec 5, 2025 - $CAPR
Capricor Therapeutics (CAPR) Valuation After Positive Phase 3 HOPE-3 Results for DMD Therapy Deramiocel
Capricor Therapeutics (CAPR) just delivered positive topline data from its pivotal Phase 3 HOPE-3 trial of Deramiocel in Duchenne muscular dystrophy, a key late stage milestone that immediately sharpens the market’s focus on this stock. See our latest analysis for Capricor Therapeutics. The HOPE-3 win arrives after a spectacular run, with a 30 day share price return of about 394 percent and a 1 year total shareholder return of roughly 136 percent. This is a clear sign that momentum is... Dec 4, 2025 - $CAPR
Capricor Therapeutics Announces Proposed Public Offering of Common Stock
SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the commencement of a proposed underwritten public offering of shares of its common stock. In addition, Capricor intends to grant the underwriters a 30-day option to purchase an additional number of shares of common stock equal to 15% of the aggregate number of shares of its common stock sold in the public Dec 4, 2025 - $CAPR
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple